key: cord-0776749-tk189gyz authors: Swai, Joel; Gui, Ming; Long, Mao; Wei, Zhu; Hu, Zixuan; Liu, Shaojun title: Humoral and cellular immune response to severe acute respiratory syndrome coronavirus‐2 vaccination in haemodialysis and kidney transplant patients date: 2021-09-27 journal: Nephrology (Carlton) DOI: 10.1111/nep.13974 sha: ebd814cfa25ddb6789e7bdcc35bb2905c0b3a032 doc_id: 776749 cord_uid: tk189gyz End‐stage renal disease (ESRD) patients are amongst the vulnerable groups and thus prioritized in the Coronavirus disease‐2019 vaccination programmes. However, this cohort was excluded from vaccine‐trials and yet shares the same vaccination scheme with the general population. Here, we explore trends of immune response‐proportions amongst ESRD patients on renal replacement therapy for up to 4 weeks post‐vaccination completion with Pfizer/Moderna vaccines. From inception to 10 July 2021, we searched six online‐databases for articles reporting humoral and cellular immune response proportions for up to 4 weeks post booster‐vaccination. We pooled the responders' proportions by meta‐analysis and conducted a meta‐regression stratifying outcomes by significant confounders. Twenty‐seven eligible studies reported 2789 ESRD patients. 1337, 1452 and 477 were on haemodialysis, received kidney transplantation, and healthy controls, respectively. Haemodialysis patients' proportions of humoral and cellular immune responses varied from 87.29% (80.77–93.81)–88.78% (86.76–90.80) and 62.86% (56.56, 69.17)–85.78% (78.99, 92.57), respectively, between first‐ and fourth‐weeks. Kidney transplant patients' proportions of humoral and cellular immune responses ranged from 2.6% (0.06–13.48)–29.87% (27.68, 32.07) and 5.13% (0.63–17.3)–59.84% (54.57–65.10), respectively, between first‐ and fourth‐weeks. All healthy controls maintained ≥93% proportions of both responses throughout the follow‐up. Study design and country of study influenced the pooled response proportions. Conclusively, haemodialysis and kidney transplant patients have lower proportions of humoral and cellular immune responses than healthy controls. However, haemodialysis patients' response proportions improve, reaching near healthy‐control levels by the fourth week. Kidney transplant patients' lower responses' proportions also improve but remain significantly lower than healthy controls throughout four‐weeks. The “one‐size‐fits‐all” vaccination scheme might be inadequate for kidney transplant patients. This meta-regression analysis demonstrated varying humoral and cellular immune responses to mRNA coronavirus vaccination amongst haemodialysis and kidney transplant patients. Chronic kidney disease (CKD) increases the risk for worsening Coronavirus Disease 2019 (COVID-19). 1 pre-existing autoimmune renal disorders have a higher risk of relapse 2 and mortality. 3 Moreover, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) can cause damage to a healthy kidney through directly infecting renal cells and mediate tubular pathogenesis through dysregulated inflammation and cytokine storm necessitating renal replacement therapy (RRT). 4 COVID-19 affects between 20% and 25% of end-stage renal disease (ESRD) patients on RRT, causing 16%-32% fatalities. 5 Race/ ethnicity (non-Hispanic Black, Hispanic and Asian), age >60 years, obesity and type-2-diabetes increase the risk of adverse outcomes. 6, 7 In addition, kidney transplant patients with COVID-19 are 1.28 times more likely to die than matched-haemodialysis patients. 5 In less than 2 years since the declaration as a pandemic, breakthroughs in the management of COVID-19 have transpired. 8 These include advances in supportive care, pharmacological treatment, therapeutic antibodies from convalescent patients' sera and vaccines. 8 Available vaccines are based on several modes of actions including inactivated virus (i.e., CoronaVac), viral subunit (i.e., NVX-CoV2373), viral-vector (i.e., ChAdOx1 nCoV- 19) or messenger ribonucleic-acid (mRNA) vaccines (i.e., BNT162b2/Pfizer vaccine, mRNA-1273/ Moderna vaccine). 9 Different vaccines have proven adequate efficacies in relative-risk-reduction (RRR) of severe COVID-19 disease and deaths. Moreover, anti-SARS-CoV-2-Spike antibodies developed through full-dose vaccination have shown to be more effective (including against variants of concern) than those isolated from convalescent patients' sera. 10 With health authorities extending vaccines provision, it is evident that ESRD patients on RRT, amongst other highly vulnerable groups, need to be prioritized. However, this cohort was largely excluded from the initial vaccine trials. 11 Yet, the current vaccine schemes in this cohort are generalized to that of the general population. Data for this cohort regarding pharmacodynamics and effectiveness of the vaccine in inducing humoral or cellular immunity against SARS-CoV-2 is currently debatable or scarce. 12 In addition, there are concerns that COVID-19 vaccination exacerbates autoimmune renal diseases, 2 and uremia and use of immunosuppressives (i.e., in kidney transplantation) lower immune response, hence low-vaccine efficacy. 11, 13 Our present study aims to explore the trends of humoral and cellular immune response proportions amongst ESRD patients on RRT from the first through fourth-week postcompletion of vaccination with mRNA vaccines. We abode by PRISMA guidelines, Supplementary Material S1. We included original research reporting the proportions of humoral or cellular immune response amongst adult patients on haemodialysis or who received kidney transplantation (and healthy controls) between the first and fourth weeks after completion of SARS-CoV-2 vaccination with mRNA vaccines. Only articles published in English or Chinese were eligible for inclusion. We excluded reviews, duplicates, animal studies and preprints. We excluded studies reporting patients who received single vaccine dose or kidney transplantation with another organ transplantation. Studies involving the paediatric population or positive SARS-CoV-2 seroconversion before the first vaccination dose were also ineligible. We searched PubMed, Google Scholar, EMBASE, SCOPUS, Chinese database National Knowledge Infrastructure (CNKI) and the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry. The searches were conducted from conception until 10 July 2021. We used advanced search tools in all the databases, firstly utilizing keywords and repeated with MeSH terms (see Supplementary Table S1 for detailed search strategy). We searched for additional sources from screening the reference lists of eligible articles, references of review articles, and google search for published articles using a combination of free texts: immune response, SARS-CoV-2 vaccination, haemodialysis and kidney transplant patients. We utilized automation-and human-based search to decide on inclusion. We had four primary endpoints: (1) Proportion of humoral immunity responders amongst haemodialysis patients after vaccine completion with an mRNA vaccine; (2) the proportion of cellular immunity responders amongst haemodialysis patients after vaccination-completion with an mRNA vaccine; (3) the proportion of humoral immunity responders amongst kidney transplant patients after vaccination completion with an mRNA vaccine; and (4) the proportion of cellular immunity responders amongst kidney transplant patients after vaccination completion with mRNA vaccine. These endpoints were re-recorded at the first, second, third and fourth-week post-vaccination completion. We recorded authors' names, year of publication, study setting, study design, sample size, demographic data and RRT type used. Data regarding vaccination included the name of vaccine administered, number of doses and their intervals, SARS-CoV-2 serostatus before vaccination, name of the diagnostic test and the definition of the positive immune response. Humoral immune response was defined as the development of detectable titre levels of anti-SARS-CoV-2 immunoglobulin-G (IgG), namely anti-Spike-IgG seroconversion. Cellular immunity response was defined as the development of spike-stimulated antigen-reactive T-helper cells. Our results were compatible with all outcome domains in all the studies retrieved. We utilized the Newcastle-Ottawa scale (see Supplementary Material S3) to assess the bias in each of the included studies. The NOS is designed to use one or two stars (*) to rank the extent of potential bias in the participants' selection, addressing confounders and measuring the outcome. The total number of stars ranks the overall study quality as low, moderate or high. We utilized funnel plots to explore publication biases caused by the studies' different sizes (i.e., small-study effect). The plots were generated by metafunnel command: metafunnel ln(proportion) se whereby ln(proportion) is the logit-transformation of the responder's proportions. The plot asymmetries were quantified by Egger's test under the Null-hypothesis that there is no small-study effect. We executed the metabias command: metabias ln(proportion) se, egger to calculate Egger's test value. We explored heterogeneity by sensitivity analyses. We performed metaregression stratifying each outcome by country of study, study design (i.e., cohort or case-control), type of vaccine administered (i.e., BNT162b2, mRNA-1273, or both), and participants' age (i.e., > or ≤60). We used the STATA's command: metareg ln(proportion) cf, wsse(se) eform whereby cf is the confounding factor (i.e., country of study, studydesign, vaccine type or participants' age) and eform is the exponential form. We used Knapp-Hartung as opposed to the DerSimonian-Laird method modifying effects in the random-effect model. We generated the linear plots by the STATA's command: metareg ln(proportion) cf, wsse(se) graph. In outcomes with an insufficient number of studies to perform meta-regression, we conducted descriptive analyses. We assessed the certainty for each outcome by using the online version of Grading of Recommendations Assessment, Development and Evaluation (GRADE) named GRADEPro. 15 We based the assessment on the number of studies, study design, risk of bias, inconsistency, indirectness and imprecision. The overall certainty for each pooled proportion was graded as very low, low, moderate and high. The search resulted in a total of 1397 records, out of which 1106 were excluded as duplicates, flagged ineligible by automated tools and one was a registered proposal. 16 We (human-based) excluded 264 studies through screening and eligibility criteria reasons. The latter involved studies reporting vaccinated before kidney transplantation; 17 patients assessed after first dose only; 18, 19 paediatric population; 20 preprints; 21 and studies that involved vaccination of covid-19 seroconverted patients. 22, 23 We found 27 studies eligible. Figure 1 summarizes the study selection process. Table 1 Four studies 28 Cellular immunity amongst kidney transplants increased with time but remained significantly lower than the control counterpart, Figure 3D . We reported the cohort studies and case-control study appraisals separately in Supplementary Table S2 Note: None of the studies reported outcomes stratified by the SARS-CoV-2 variant of concern/interest. All kidney transplant patients were on immunosuppressive medication. Abbreviations: CLIA, chemiluminescent immunoassay; HD, haemodialysis; KT, kidney transplant; NA, exact data not accessed (i.e., present in a figure) ; NR, not reported; USA-United States of America. a Only patients fitting criteria were included in the current analysis. b Only non-exposed patients are included in the present analysis. Supplementary Figure S2 summarizes the funnel plots exploring publication biases. We illustrated funnel plots for haemodialysis patients at 1-4 weeks, controls at the fourth week, and cellular immunity at the third and fourth weeks. We also reported Therefore, our study was not significantly influenced by publication biases. We stratified the analyses by country of study, study design, vaccine type and participant's age. We reported regression plots for findings for humoral immune responses for haemodialysis and kidney transplant patients during the fourth week. In other outcomes, metaregression was inapplicable because of an insufficient number of studies. F I G U R E 3 Trends of immune responses for participants from the first through fourth weeks post-vaccination completion. The trend of proportions of (A) humoral immunity and (B) cellular immune responders amongst the haemodialysis patients and healthy controls. Trends of proportions of (C) humoral immunity and (D) cellular immunity responders' proportions amongst kidney transplant patients compared to healthy controls. We did not find data for the third week of humoral. We did not find cellular response data for the first (controls), second and third weeks We explored the humoral and cellular immune response amongst in Germany. 36 We call upon robust original studies exploring this hypothesis. In addition, cohort studies demonstrated higher humoral responses than case-control studies (p-value = .0045) for the same reason explained earlier, Figure 7C . Interestingly, studies administering both vaccines (not to the same patient) had a non-significant (pvalue = .168) highest response, followed by Pfizer then Moderna, Figure 7D . increased from 5% to about 59.84% between first and fourth weeks, respectively, Figure 3D . We found only one study reporting controls in this outcome at the fourth week (96%). However, at this point, the cellular immune response for healthy controls is well established as high (>90%). 29 The lower cellular response is significantly attributed to immunosuppressive therapy, as explained earlier. Interestingly, the cellular response amongst kidney transplant patients is higher by the fourth week (59.84%) than that of the humoral counterpart, 29.87%. This finding might mean immunosuppression affects humoral immunity more than cellular immunity; thus, the latter might confer some, though not adequate, protection in this cohort. We provide evidence that the current "one-size-fits-all" vaccination programme leaves kidney transplant patients vulnerable and needs to be individualized. Therefore, we call upon robust clinical trials in this vulnerable cohort. The individualized vaccination plan might consider: Vaccinating before transplantation (if possible); 19 giving more than two doses; 18, 25, 27 or developing a scheme that combines different vaccine platforms to improve vaccines immunogenicity. 34 However, we should continue promoting safety measures by maintaining physical distancing, avoiding crowds, quarantining and wearing facemasks before and after vaccination. We excluded pre-prints as they have not been certified by peerreview; however, significant evidence might be available in the preprints. Moreover, we did not find studies reporting our outcome stratified by the SARS-CoV-2 variants of concern as their altered immunogenicity also affects immune response mounting. 49 We used IgG response to assess humoral immunity; however, IgA also protects against respiratory infections. 50 Also, different immune response measurement-kits have different sensitivities (i.e., 89%-97%) and specificities (i.e., 99%-100%). 51 Moreover, studies were conducted in different settings, meaning different healthcare standards, local guidelines and burdens exerted on healthcare facilities due to the COVID-19 pandemic. 52 3.14 | Conclusions The author declares that there is no conflict of interest. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination Coronavirus disease 2019 and kidney transplantation in Saudi Arabia: outcomes and future opportunities Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection Results from the ERA-EDTA registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe Elevated monocyte to lymphocyte ratio and increased mortality among patients with chronic kidney disease hospitalized for COVID-19 Initial effects of COVID-19 on patients with ESKD Features, Evaluation, and Treatment of Coronavirus (COVID-19) COVID-19 vaccine: critical questions with complicated answers BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced Humoral response after SARS-Cov-2 mRNA vaccine in a cohort of hemodialysis patients and kidney transplant recipients Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine Metan: fixed-and random-effects meta-analysis GRADEpro Guideline Development Tool 2020 (developed by Evidence Prime, Inc.). gradepro.org The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis, or living with a kidney transplant -a prospective, controlled, multicenter observational cohort by the REnal patients COVID-19 VACcination (RECOVAC) consortium COVID-19 VACcination (RECOVAC) consortium Persistent immunogenicity of the mRNA COVID-19 vaccine in patients vaccinated before kidney transplant. Transplantation Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients Kidney transplant recipients rarely show an early antibody response following the first COVID-19 vaccine administration Assessment of seroconversion to SARS-CoV-2 in a cohort of pediatric kidney transplant recipients Immunogenicity of SARS-CoV-2 vaccine in dialysis. medRxiv Immunogenicity and reactogenicity after SARS-CoV-2 mRNA vaccination in kidney transplant recipients taking Belatacept Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients Poor Anti-SARS-CoV-2 humoral and t-cell responses after 2 injections of mRNA vaccine in kidney transplant recipients treated with Belatacept High immunogenicity of a messenger RNA based vaccine against SARS-CoV-2 in chronic dialysis patients Delayed second dose versus standard regimen for covid-19 vaccination Humoral response after three doses of BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients Humoral and cellular responses to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines administered to hemodialysis patients Immunogenicity of COVID-19 tozinameran vaccination in patients on chronic dialysis Early humoral responses of hemodialysis patients after COVID-19 vaccination with BNT162b2 Serological response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients depends on prior exposure to SARS-CoV-2 Impaired humoral response in renal transplant recipients to SARS-CoV-2 vaccination with BNT162b2 (Pfizer-BioNTech) Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus Humoral response to SARS-CoV-2-vaccination with BNT162b2 (Pfizer-BioNTech) in patients on hemodialysis Humoral response of the mRNA-1273 SARS-CoV-2 vaccine in peritoneal dialysis patients Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study Early experience with SARs-CoV-2 mRNA vaccine breakthrough among kidney transplant recipients Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients Antibody response to mRNA-1273 SARS-CoV-2 vaccine in hemodialysis patients with and without prior COVID-19 Efficacy of the BNT162b2 mRNA Covid-19 vaccine in a hemodialysis cohort Postvaccine anti-SARS-CoV-2 spike protein antibody development in kidney transplant recipients Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis Factors that influence the immune response to vaccination New variants of SARS-CoV-2 The role of secretory antibodies in infection immunity Side-byside comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity Covid-19 is causing the collapse of Brazil's national health service Humoral and cellular immune response to severe acute respiratory syndrome coronavirus-2 vaccination in haemodialysis and kidney transplant patients